A compound of Formula or Formula (Ia), a pharmaceutically acceptable salt, polymorph, solvate, N-oxide, or stereoisomer thereof: wherein: M is a bond, -O-, -S-, -S -, SO 2 -, or -N(R 4)-; m is 0, 1, or 2; provided that when HetA is attached to (CR 1 R 2) m through a ring nitrogen atom, m = 0 or 2; n is 0, 1, 2, or 3; provided that when n is 0, then M is a bond; p is 1, 2, or 3; X 1 and X 2 are independently selected from -OH, -OR 8, or F; Z is >C=O, >C=S, or >SO 2; HetA is a non-aromatic heterocyclic ring system; at least one Y is selected from the group consisting of -NR 4 R 5,-NR 4 C(=NR 5)NR 4 R 5, -C(=NR 4)NR 4 R 5, -N(R 4)C(=NR 5)R 6, -(CR 6 R 7) v NR 4 R 5,-(CR 6 R 7) v N(R 4)C(=NR 5)NR 4 R 5, -NR 4 (CR 6 R 7) v NR 4 R 5, -NR 4 (CR 6 P, 7) v OR 10,-(CR 6 R 7) v NR 4 (CR 6 R 7) v NR 4 R 5, -NR 5 C(=NR)NR 4 (CR 6 R 7) v NR 4 R 5,-NR 4 (CR 6 R 7) v N(R 4)C(=NR 5)NR 4 R 5, -NR 5 C CR 6 (NR 4 R 5)(CR 6 R 7) v NR 4 R 5,-(CR 6 R 7) v C(=NR 5)NR 4 R 5, -(CR 6 R 7) v N(R 4)C (CR 6 R 7) v NR 4 R 5,-C(=NR 4)NR 4 C R 6, -NR 4 (CR 6 R 7) v Heteroaryl, and -O(CR 6 R 7) v NR 4 R 5; v is 1-4; R a, R b, and R c are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl, -OH, -OR 10, -NR 4 R 5, and -SR 10; R 1 and R 2 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -OH, -OR 10, -SR 10, and -NR 4 R 5, or R 1 and R 2 taken together form an oxo, oxime, a carbocycle or heterocycle with the carbon to which they are attached; R 3 is hydrogen or C 1 -C 6 alkyl; R d, R 4 and R 5 are independently selected from the group consisting of hydrogen, -OH, -CN, C 1 -C 6 alkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, heteroaralkyl, (poly-ethylene-glycol)-ethyl, and a saccharide; or R 4 and R 5 taken together form a heterocycle with the nitrogen to which they are attached; R 6 and R 7 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C 1 -C 6 alkyl, alkoxyalkyl, hydroxyalkyl, C 3 -C 6 cycloalkyl, -OH, -OR 10, -SR 10, -NR 4 R 5, -NR 4 C R 5, -C NR 4 R 5, -NR 4 SO 2 R 5, heterocyclyl, aryl, and heteroaryl; or R 6 and R 7 taken together form an oxo, oxime, a carbocycle or aheterocycle with the carbon to which they are attached; R 8 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or a pharmaceutically acceptable boronate ester group; and R 10 is C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl. M is a bond, -O-, -S-, -S -, SO 2 -, or -N(R 4)-; m is 0, 1, or 2; provided that when HetA is attached to (CR 1 R 2) m through a ring nitrogen atom, m = 0 or 2; n is 0, 1, 2, or 3; provided that when n is 0, then M is a bond; p is 1, 2, or 3; X 1 and X 2 are independently selected from -OH, -OR 8, or F; Z is >C=O, >C=S, or >SO 2; HetA is a non-aromatic heterocyclic ring system; at least one Y is selected from the group consisting of -NR 4 R 5,-NR 4 C(=NR 5)NR 4 R 5, -C(=NR 4)NR 4 R 5, -N(R 4)C(=NR 5)R 6, -(CR 6 R 7) v NR 4 R 5,-(CR 6 R 7) v N(R 4)C(=NR 5)NR 4 R 5, -NR 4 (CR 6 R 7) v NR 4 R 5, -NR 4 (CR 6 P, 7) v OR 10,-(CR 6 R 7) v NR 4 (CR 6 R 7) v NR 4 R 5, -NR 5 C(=NR)NR 4 (CR 6 R 7) v NR 4 R 5,-NR 4 (CR 6 R 7) v N(R 4)C(=NR 5)NR 4 R 5, -NR 5 C CR 6 (NR 4 R 5)(CR 6 R 7) v NR 4 R 5,-(CR 6 R 7) v C(=NR 5)NR 4 R 5, -(CR 6 R 7) v N(R 4)C (CR 6 R 7) v NR 4 R 5,-C(=NR 4)NR 4 C R 6, -NR 4 (CR 6 R 7) v Heteroaryl, and -O(CR 6 R 7) v NR 4 R 5; v is 1-4; R a, R b, and R c are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocyclyl, aryl, heteroaryl, -OH, -OR 10, -NR 4 R 5, and -SR 10; R 1 and R 2 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, -OH, -OR 10, -SR 10, and -NR 4 R 5, or R 1 and R 2 taken together form an oxo, oxime, a carbocycle or heterocycle with the carbon to which they are attached; R 3 is hydrogen or C 1 -C 6 alkyl; R d, R 4 and R 5 are independently selected from the group consisting of hydrogen, -OH, -CN, C 1 -C 6 alkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, aralkyl, heteroaralkyl, (poly-ethylene-glycol)-ethyl, and a saccharide; or R 4 and R 5 taken together form a heterocycle with the nitrogen to which they are attached; R 6 and R 7 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, C 1 -C 6 alkyl, alkoxyalkyl, hydroxyalkyl, C 3 -C 6 cycloalkyl, -OH, -OR 10, -SR 10, -NR 4 R 5, -NR 4 C R 5, -C NR 4 R 5, -NR 4 SO 2 R 5, heterocyclyl, aryl, and heteroaryl; or R 6 and R 7 taken together form an oxo, oxime, a carbocycle or aheterocycle with the carbon to which they are attached; R 8 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or a pharmaceutically acceptable boronate ester group; and